key: cord-0952948-5znm0mq5
authors: De Spiegeleer, Anton; Bronselaer, Antoon; Teo, James T.; Byttebier, Geert; De Tré, Guy; Belmans, Luc; Dobson, Richard; Wynendaele, Evelien; Van De Wiele, Christophe; Vandaele, Filip; Van Dijck, Diemer; Bean, Dan; Fedson, David; De Spiegeleer, Bart
title: The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents
date: 2020-06-15
journal: J Am Med Dir Assoc
DOI: 10.1016/j.jamda.2020.06.018
sha: e4e4ee2faeec4a6e959d3ad55aa71390f4c348a3
doc_id: 952948
cord_uid: 5znm0mq5

Abstract Objectives Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and HMG-CoA reductase inhibitors (‘statins’) have been hypothesised to impact COVID-19 severity. However, up till now, no studies investigating this association were conducted in the most vulnerable and affected population groups, i.e. older adults residing in nursing homes. The objective of this study has been to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older adults residing in nursing homes. Design We undertook a retrospective multi-centre cohort study to analyse the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The outcomes were 1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and 2) asymptomatic, i.e. no disease symptoms in the whole study-period while still being PCR diagnosed. Setting and participants A total of 154 COVID-19 positive subjects was identified, residing in one of two Belgian nursing homes that experienced similar COVID-19 outbreaks. Measures Logistic regression models were applied with age, sex, functional status, diabetes and hypertension as covariates. Results We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (OR 2.91; CI 1.27-6.71), which remained statistically significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 2.72; CI 0.59-25.1) or serious clinical outcome (OR 0.48; CI 0.10-1.97). Conclusions and Implications Our data indicate that statin intake in old, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. The role of statins and renin-angiotensin system drugs need to be further explored in larger observational studies as well as randomised clinical trials.

and hypertension as covariates.

Results. We found a statistically significant association between statin intake and the absence 24 of symptoms during COVID-19 (OR 2.91; CI 1.27-6.71), which remained statistically 25 significant after adjusting for covariates (OR 2.65; CI 1.13-6.68). Although the effects of 26 statin intake on serious clinical outcome were in the same beneficial direction, these were not 27 statistically significant (OR 0.75; CI 0.24-1.87). There was also no statistically significant NCT04348695, NCT04343001, NCT04351581). However, the estimated completion dates for 51 these trials will be some time in 2021, and most will only consider ARB/ACEi monotherapy, 52 i.e. not in combination with statins. 53 To our knowledge, no ARB/ACEi/statin studies have been or are being conducted among 54 elderly nursing home residents, the most vulnerable individuals for COVID-19 morbidity and mortality. In Belgium, a country with a well-developed health care system, 3000 test, the symptoms used for determining disease onset were defined more strictly, i.e., 86 respiratory complaints (cough, shortness of breath, sore throat, runny nose), fever (T° > 87 37.6°C), increased oxygen-need or low oxygen saturation (SpO2 ≤ 92%).

The primary outcomes were 1) serious COVID-19, i.e. long-stay hospital admission (length of 89 stay ≥ 7 days) or death (at nursing home or hospital) within 14 days of disease onset, and 2) 90 asymptomatic, i.e. no disease symptoms as defined above throughout the whole study-period 91 while still being PCR diagnosed.

Information about daily drug intake was available through the medication administration 93 records at nursing home level. All residents were stratified according to drug exposure to 94 ACEi or ARB within 7 days before the day of disease onset or during the disease (prior to an 95 outcome being reached). Specifically, we considered as treated all residents taking ≥ 2 days 96 an ACEi (ramipril, lisinopril, enalapril, captopril, quinapril, imidapril, fosinopril, trandolapril) 97 or ARB (candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan) up to 7 days 98 before or 14 days after disease onset. Only one day of drug intake (e.g. for acute 99 hypertension) was not considered as (chronic) treatment. An identical protocol was used to 100 stratify according to drug exposure to statins (atorvastatin, fluvastatin, pravastatin, 101 rosuvastatin, simvastatin).

As no direct diagnosis codes were available, we developed a mapping table based on clinical 103 drug prescriptions to determine the diabetic and hypertension status of all residents. It was designed by a specialist in elderly care and validated by two independent physicians, one a 105 general physician and the other a cardiologist.

The functional status of all residents was a dichotomous variable (high vs. low functioning).

This definition was based on the available Katz scale for residents before day of disease onset.

The Katz scale is a measure of independent activity of daily living.

Data collection and quality control 110 Data about residents was available at the level of nursing homes. After anonymization, these 111 data were merged in a relational database for further processing by making use of Extract, 112 Transform, and Load (ETL) techniques. All received anonymized data were then evaluated on 113 basic data quality attributes such as completeness (i.e., the extent of missing data) and 114 accuracy (i.e., whether or not suspicious outliers were present in the individual attributes). This procedure has been used previously by our group and shown to be robust for low 129 prevalence events and low-dimensional settings 19, 26, 27 . We first explored the independent 130 association between ACEi/ARB and both outcomes, as well as the association between statins 131 and the same outcomes. Then we adjusted the models stepwise for age, sex, functional status, 132 hypertension, and diabetes mellitus. Also the method of diagnosis (PCR or clinical) was 133 evaluated as possible confounder. All statistical analyses were performed using SAS 9.4 (SAS 

The study cohort included 154 COVID-19-diagnosed residents aged 86±7 (mean±SD) years, 148 evenly distributed over the two nursing homes (76 and 78 residents, respectively). Baseline 149 characteristics are shown in Table 1 . In our cohort (33% male), 20% were taking Table 2) . 185 We also examined associations between ACEis/ARBs and statins, and serious COVID-19.

Although the available data failed to reach statistical significance, the directionality of the (Supplementary information S1) . 198 We did not undertake regression analyses on the combined ACEi/ARB+statin group as there 199 were only eight residents in our cohort; nor did we undertake separate analyses for the ACEi 200 or ARB groups; only six residents were treated with an ARB. Sensitivity analyses were conducted on the statistically significant association between statins 202 and symptoms. We found that estimates of the impact of statin treatment on asymptomatic 203 status were consistently of the same magnitude and statistically significant as the original 204 analyses (Supplementary information S2) . only death as serious COVID-19, the effect sizes become even larger and reach statistical 220 significance ( Table S1) 

Although this result is promising, our sample size was too small to allow us to draw firm 239 conclusions. The authors have declared no competing interest. were taken with change of the hypertension status for all subjects of this sample. For each sample the 20 odds ratio for statin intake and asymptomatic status adjusted for age, gender, functional status, 21 diabetes mellitus and hypertension was calculated. The y-axis shows these odds ratios: boxplots 22

represent median (midline), 25% and 75% percentiles (upper and lower perimeters) and 1.5x IQR 23

(whiskers). The x-axis indicates the chosen sample size. A horizontal line at y = 1 represents the line 24 of no effect. 25 Katz scale indicating a small decrease in functional status or unknown status (n = 56) were taken with 30 change of the functional status for all subjects of this sample. For each sample the odds ratio for statin 31 intake and asymptomatic status adjusted for age, gender, functional status, diabetes mellitus and 32

hypertension was calculated. The y-axis shows these odds ratios: boxplots represent median (midline), 33

25% and 75% percentiles (upper and lower perimeters) and 1.5x IQR (whiskers). The x-axis indicates 34 the chosen sample size. A horizontal line at y = 1 represents the line of no effect. 

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS 291 coronavirus-induced lung injury

Angiotensin-converting enzyme 2 protects from severe acute lung 293 failure

Imbalance Between Pulmonary Angiotensin-295

Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in Acute Respiratory Distress 296 Syndrome

Acute respiratory distress syndrome 298 leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin 299 II receptor antagonist

Treating the host response to emerging virus diseases: lessons learned from 301 sepsis, pneumonia, influenza and Ebola

The Role of Cytokines including Interleukin-303 6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Why the Immune Mechanisms of 306 Pulmonary Intravascular Coagulopathy in COVID-19 Pneumonia are Distinct from Macrophage 307 Activation Syndrome with Disseminated Intravascular Coagulation

Abnormal coagulation parameters are associated with poor 310 prognosis in patients with novel coronavirus pneumonia

Difference of coagulation features between severe pneumonia 313 induced by SARS-CoV2 and non-SARS-CoV2

A revised systematic review and meta-analysis on 317 the effect of statins on D-dimer levels

Evaluation of protein C and protein S 319 levels in patients with diabetes mellitus receiving therapy with statins and ACE inhibitors or 320 angiotensin II receptor blockers

COVID-19: the vasculature unleashed

Hiding in Plain Sight: an Approach to Treating Patients with 324 Severe COVID-19 Infection

Statins and the COVID-19 main protease: in silico 326 evidence on direct interaction

Prior use of both a statin and ARB is associated with lower mortality 328 for patients hospitalized with pneumonia

Population-Based Study of Statins, Angiotensin 330 II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related 331 Outcomes

Renin-angiotensin system inhibitors improve the clinical 333 outcomes of COVID-19 patients with hypertension

Treatment with ACE-inhibitors is associated with less 335 severe SARS-Covid-19 infection in a multi-site UK acute Hospital Trust

Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in 339 COVID-19 Patients With Hypertension

Anti-hypertensive Angiotensin II receptor blockers 341 associated to mitigation of disease severity in elderly COVID-19 patients

Association of Inpatient Use of Angiotensin Converting Enzyme 344 Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension 345 Hospitalized With COVID-19. Circulation

Clinical Presentation of COVID-19: A Systematic Review Focusing on 349 Upper Airway Symptoms. Ear, nose, & throat journal

Firth logistic regression for rare variant association tests

BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES

Epidemiology of Covid-19 in a Long-Term Care 355 Facility in King County

Case-Fatality Rate and Characteristics of Patients Dying in 357 Relation to COVID-19 in Italy

Covid-19: Deaths in care home deaths in England and Wales rise sharply

Angiotensin Receptor Blockers and Outcome of COVID-19 : A Systematic Review and Meta-analysis

Association of Treatment Dose Anticoagulation with In-364 Hospital Survival Among Hospitalized Patients with COVID-19

Compassionate Use of Remdesivir for Patients with Severe 368 Covid-19. The New England journal of medicine

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe 370 Covid-19. The New England journal of medicine

A systematic review on the efficacy 372 and safety of chloroquine for the treatment of COVID-19

The convalescent sera option for containing COVID-19. The Journal 374 of clinical investigation

COVID-19 enters the cell through ACE2 receptors, thereby 386 decreasing these membrane-bound receptors, and relatively stimulating the RAS system

MyD88 at normal levels and down regulate NFkB. Black lines = stimulating effects

We thank all of the staff of VZW Zorg-Saam Zusters Kindsheid Jesu for their daily care of older people and for their collaboration on this study during these difficult times. We also thank the staff of the Corilus Health IT Center who helped with the data extraction.